Reported about 14 hours ago
U.S. FDA researchers revealed that the popular asthma drug Singulair (montelukast), initially promoted as safe, may be linked to serious neuropsychiatric issues, including suicidal thoughts. Although it has been prescribed widely since 1998, thousands of adverse event reports prompted the FDA to add a warning label in 2020, indicating potential mental health risks. Recent findings showed significant binding of the drug to brain receptors, raising concerns about its impact on mood and cognition, although more research is required to determine specific risks.
Source: YAHOO